Yet another damning article about the aluminum exposure of infants through vaccine products.
For Immediate Release - Pittsburgh, PA
1. A study of the toxicity of the doses of aluminum in vaccines, led by Dr. James Lyons-Weiler of the publicly funded Institute for Pure and Applied Knowledge, was motivated by an absence of appropriate testing of aluminum safety testing in vaccines. Dosage safety testing of metals in vaccines is not required by federal regulatory bodies.
2. The research represent an objective and independent evaluation of an important aspect of the CDC's vaccine schedule safety.
3. The study builds on prior work that established a "safe" baseline of Al in vaccines for infants derived from FDA limits for adults, corrected for body weight per dose.
4. A Key Finding is that the CDC schedule likely induces Al toxicity in newborns for over 70 percent of their days in the first seven months of life. This represents chronic aluminum toxicity during a critical period of brain development.
5. The IPAK research team, which included a Board-certified pediatrician, also studied an alternative schedule (the "Vaccine Friendly Plan") and found can be expected to result in aluminum toxicity in only 5% of days over the same time period.
6. In the study discussion, the team has called on the FDA to conduct dose-escalation studies of body-weight adjusted injected forms of aluminum in infant mice to assess the safety of the CDC recommended schedule for humans.
Aluminum is known to induce autoimmunity in mice, rats, and humans. About 60% of vaccines on the CDC schedule contain aluminum.
Ongoing research by scientists at IPAK includes a study of the effects of CDC recommended catch-up schedules on aluminum chronic and total toxicity, and to define strategies to reduce total aluminum load during catch-up efforts via careful brand choice and spacing out aluminum-containing vaccines. Tens to hundreds of thousands of families are expected to vaccinate their older children for the first time due to loss of religious and medical exemptions, and therefore pediatricians should especially take heed of the findings of this study.
This research is expected to reduce the incidence of autoimmune disorders in US children and adults.
Journal of Trace Elements in Medicine and Biology
Volume 58, March 2020, 126444
Acute exposure and chronic retention of aluminum in three vaccine schedules and effects of genetic and environmental variation
Author links open overlay panel GrantMcFarlandaElaineLa JoieaPaulThomasbJamesLyons-Weilera
Like the mechanisms of action as adjuvants, the pharmacodynamics of injected forms of aluminum commonly used in vaccines are not well-characterized, particularly with respect to how differences in schedules impact accumulation and how factors such as genetics and environmental influences on detoxification influence clearance. Previous modeling efforts are based on very little empirical data, with the model by Priest based on whole-body clearance rates estimated from a study involving a single human subject.
In this analysis, we explore the expected acute exposures and longer-term whole-body accumulation/clearance across three vaccination schedules: the current US Centers for Disease Control and Prevention (CDC) schedule, the current CDC schedule using low aluminum or no aluminum vaccines, and Dr. Paul Thomas’ “Vaccine Friendly Plan” schedule. We then study the effects of an implicit assumption of the Priest model on whether clearance dynamics from successive doses are influenced by the current level of aluminum or modeled by the assumption that a new dose has its own whole-body dynamics “reset” on the day of injection. We model two additional factors: variation (deficiency) in aluminum detoxification, and a factor added to the Priest equation to model the potential impact of aluminum itself on cellular and whole-body detoxification. These explorations are compared to a previously estimated pediatric dose limit (PDL) of whole-body aluminum exposure and provide a new statistic: %alumTox
, the (expected) percentage of days (or weeks) an infant is in aluminum toxicity, reflecting chronic toxicity. We show that among three schedules, the CDC schedule results in the highest %alumTox
regardless of model assumptions, and the Vaccine Friendly Plan schedule, which avoids >1 ACV per office visit results in the lowest (expected) %alumTox
. These results are conservative, as the MSL is derived from data used by FDA to estimate safety of aluminum in adult humans. These results demonstrate high potential utility of modeling variation in patient responses to aluminum. More empirical data from individuals who are suspected of being intolerant of aluminum from vaccines, evidenced by high aluminum retention, neurodevelopmental disorders and/or a myriad of chronic illnesses would help answer questions on whether the model predictions can be used to estimate parameter values tied to genetic factors including genomic sequence variation and family history of chronic illnesses tied to aluminum exposure.